Feed ACRS
AC

Aclaris Therapeutics, Inc.

ACRS · NASDAQ

$5.26 -0.94% (-$0.05)
1M -12.62%
Market Cap $734.6M
P/E Ratio -
Div. Yield -
ROE 61.65%
Analiză

Un raport AI despre afacere, finanțe, evaluare, sentiment, știri și riscuri - scris în câteva minute.

Piotroski F-Score Weak
2/9
Valuation
13 /100
Expensive
P/B 5.90x
P/S 89.38x
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 19.50%
Rev. growth 35.93%
FCF growth N/A
Profitability
20 /100
Weak
Net margin 921.50%
Op. margin 1,050.16%
FCF margin 756.50%
Quality
1 /100
Poor
ROE 61.65%
ROA 42.15%
Asset turnover 0.05x
Debt
100 /100
Low
Current ratio 3.46x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
43 /100
Moderate
Rev. volatility 32.56%
EPS volatility 52.34%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre ACRS
Online

Despre companie

Aclaris Therapeutics, Inc. (ACRS) is a biotechnology company focused on researching, developing, and commercializing therapeutics for dermatological conditions and skin-related health issues. The company concentrates on innovative therapeutic approaches and medicinal products that target various dermatological indications, including skin disorders and autoimmune conditions. Aclaris Therapeutics, Inc. has a strong research foundation and collaborates with skin experts and dermatologists to develop effective treatment methods. With its innovations and focus on skin health, investing in Aclaris Therapeutics, Inc. (ACRS) shares may present an interesting investment opportunity for investors interested in the biotechnology and medical sectors.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Neal S. Walker

Employees

71

Headquarters

Wayne

Evenimente viitoare

05 NOV.

Earnings

Upcoming earnings report

35d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.